相关实验视频

Updated: Mar 11, 2026

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells

Published on: June 2, 2022

合成抗体模拟剂与ROS-Gated糖释放用于向性结肠炎治疗

Yan Zhang¹, Song Li², Qiang Li¹

¹State Key Laboratory of Analytical Chemistry For Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, China.

Advanced healthcare materials

|March 10, 2026

概括

研究人员开发了用于炎症性肠病 (IBD) 的新型ROS激活纳米药物. 这些智能聚合物向炎症组织,改善愈合并重新平衡肠道微生物群.

科学领域:

生物材料科学生物材料科学
纳米医学是一种纳米医学.
胃肠病学胃肠病学

背景情况:

常规针对性治疗炎症性肠病 (IBD) 面临的挑战是由于不稳定的生物识别元素.
分子印记聚合物 (MIP) 提供了强大的合成替代品,但遭受非特异性结合,限制其有效性.
现有的疗法缺乏精确的控制在炎症环境中的目标参与.

研究的目的:

为IBD治疗设计反应性氧物种 (ROS) 激活的治疗执行器.
开发一个系统,克服静态MIP的局限性,通过实现受控的,特定地点的准.
创建智能纳米药物,以增强粘膜愈合和IBD中的微生物组调节.

主要方法:

通过ROS可切割的链接器将曼诺斯与转移林印制的MIP结合起来,以创建响应式执行器.
使用曼诺作为治疗剂和固体屏蔽,以防止运输过程中发生非特异性结合.
研究ROS触发的激活在炎症部位的高亲和性表皮向和屏障形成.

主要成果:

开发的MIP显示了双重功能:非特异性结合的固体阻断和ROS激活的向.
在小鼠结肠炎模型中,纳米药物实现了显著的粘膜愈合和炎症缓解.
观察到微生物群的再平衡,其疗效与剂量为27.2 mg/kg/d的免费曼诺斯相当.

结论:

这项研究提出了一种可通用的策略,用于开发针对性药物输送的对疾病有反应的纳米药物.
由ROS激活的MIP提供了一个有前途的平台来治疗IBD,通过实现精确的识别和局部治疗作用.
这种方法为智能纳米药物铺平了道路,适应复杂的生理环境,以改善治疗结果.

关键词:

IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD 在ROS-响应释放的释放中.有分子印记的聚合物.粘液屏障是一种粘液屏障.有针对性的糖输送.

更多相关视频

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...